UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

 

Filed by the Registrant

 

☒

 

Filed by a Party other than the Registrant

 

☐

 

 

Check the appropriate box:

☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials
☐ Soliciting Material Pursuant to § 240.14a-12

 

Talis Biomedical Corporation

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.
☐ Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
☐img257963935_0.jpg

img257963935_1.jpg

 

Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Talis Biomedical
Grafico Azioni Talis Biomedical (NASDAQ:TLIS)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Talis Biomedical